Liotyronina sodu CAS:55-06-1

Triiodothyronine, also known as T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth and development, metabolizm, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. This pathway is regulated via a closed-loop feedback process: Elevated concentrations of T3, and T4 in the blood plasma inhibit the production of TSH in the pituitary gland. As concentrations of these hormones decrease, the pituitary gland increases production of TSH, and by these processes, a feedback control system is set up to regulate the amount of thyroid hormones that are in the bloodstream.

As the true hormone, the effects of T3 on target tissues are roughly four times more potent than those of T4.Of the thyroid hormone that is produced, just about 20% is T3, mając na uwadze, że 80% is produced as T4. Roughly 85% of the circulating T3 is later formed in the thyroid by removal of the iodine atom from the carbon atom number five of the outer ring of T4. In any case, the concentration of T3 in the human blood plasma is about one-fortieth that of T4. This is observed in fact because of the short half-life of T3, which is only 2.5 days.This compares with the half-life of T4, which is about 6.5 dni.

Liotyronina jest najsilniejszą formą hormonu tarczycy. Chemicznie, jest prawie identyczna z trójjodotyroniną (T3). Jako taki, działa na organizm zwiększając podstawową przemianę materii, wpływają na syntezę białek i zwiększają wrażliwość organizmu na katecholaminy (jak adrenalina) przez pobłażliwość. Hormony tarczycy są niezbędne do prawidłowego rozwoju i różnicowania wszystkich komórek organizmu człowieka. Hormony te regulują również białko, tłuszcz, i metabolizm węglowodanów, wpływając na sposób, w jaki komórki ludzkie wykorzystują związki energetyczne.

In comparison to levothyroxine (T4), liothyronine has a faster onset of action as well as a shorter biological half-life, which may be due to less plasma protein binding to thyroxine-binding globulin and transthyretin.

Physicians can use this instead of or in addition to levothyroxine (T4) for patients undergoing thyroid withdrawal. When a patient has thyroid cancer or Graves' disease, ablation therapy with radioactive iodine can be used to remove any trace thyroid tissue. For 131I therapy to be effective, the trace thyroid tissue must be avid to iodine. The best method is to starve the tissue of iodine but this can lead to hypothyroid symptoms for the patient. Withdrawal from levothyroxine can be done but it takes six weeks of withdrawal for the remaining thyroid tissue to be completely starved. Six weeks is needed owing to levothyroxine's long half life. Six weeks can be inconvenient for the patient and delay treatment. Liothyronine instead can be taken and withdrawn from for two weeks to starve the thyroid tissue. This is much safer and more convenient than levothyroxine.